Researchers led by Shohei Suzuki, MD, PhD, and Tomohisa Sujino, PhD at Keio University reported a mechanistic link between intestinal epithelial cells and multiple sclerosis–related neuroinflammation. In mouse models of experimental autoimmune encephalomyelitis (EAE) and in tissues from patients with multiple sclerosis, they found increased TH17 cells and upregulated MHC class II expression on intestinal epithelial cells. The team reported that deleting MHC II in intestinal epithelial cells reduced pathogenic TH17 accumulation in the gut and lowered EAE severity. The paper, published in Science Immunology, frames intestinal epithelial MHC II as a driver of encephalitogenic CD4+ T cell development, connecting gut immune education to central nervous system autoimmunity. Clinically, the data point to intestinal immunity as a potential therapeutic site, particularly as current MS approaches often target B cells rather than gut antigen-presenting functions. The findings also increase the evidentiary base for interventions aimed at modulation of intestinal antigen presentation or microbiota-driven immune priming.